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Hepatitus B virus (HBV) is a major cause of the development of hepatpcellular carcinoma (HCC). One of the signiﬁcant
characteristics of tumor progression is cell migration which is reﬂective of cytoskeletal dynamics. The Rho GTPases contribute
to a multiple cellular processes, including the cellular cytoskeletal reorganization and motility. It has been found that some Rho
GTPases have oncogenic activity and can promote cancer cell invasion. Here we discuss one of the Rho GTPases, Rac1 can be
activated by HBV replication and such activation results in the high motility of HBV-replicating cells. The enhanced cell motility
can be interestingly alleviated by the mutation at the sites of proline rich domain located in HBX. Our ﬁndings may provide new
insights on the mechanism of HCC development associated with chronic HBV infection.
Copyright © 2009 Huixing Feng et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Hepatitis B virus (HBV) can cause chronic and acute
infection and remains a global health problem with a
considerable morbidity and mortality. It was estimated that
there are currently more than 350 million carriers all over
the world [1]. Chronic hepatitis B virus (HBV) infection is
a major cause of hepatocellular carcinoma (HCC) [2]. HBV
chronic carriers, including those carrying vaccine-escape
mutants [3], have a greater than 100-fold increased relative
risk of developing the tumor [4]. Despite characterization
of integrated HBV genome in chromosomes of HCC [5], a
comprehensive understanding of the underlying mechanism
needs further elucidation.
Tumorprogressionisacomplexmultistageprocess,mak-
ing the cells from normal to malignant by a series of alter-
ations including cell adhesion and movements. One of the
important characteristics of the tumor cells is that they have
the ability to escape from the normal controls during pro-
liferation, diﬀerentiation, apoptosis, and migration [6]. In
metastasis, tumor cells detached from their place of forma-
tion, move, and form new tumors in distant healthy tissues.
Cell migration is a key activity of many important
normal and abnormal biological processes, including tumor
cell metastasis [7]. Invasion and metastasis are essential
hallmarks of malignant cancer cells. Adhesion of tumor cells
to host cell layers and subsequent transcellular migration are
importantprocessesincancerinvasionandmetastasis,which
involves the extracellular matrix (ECM) degradation [8–10].
High motility and cell migration might be the premonition
of malignancy of chronic viral infection.
The Rho small GTPases, which contains the Rho, Rac,
Cdc42 subfamilies, regulate cell migration through the
reorganization of actin cytoskeleton, which is considered as
a driving force of cell motility [11, 12]. The Rho GTPases
act as molecular switches cycling between active GTP-bound
forms and inactive GDP-bound forms [13]. Such cycling is
regulated by guanosines nucleotide exchange factors (GEFs)
andGTPase-activatingproteins(GAPs)[14].TheRhofamily
has been implicated in many steps during the cellular
transformation. In addition, Rho GTPases activation has
been linked to virus replication such as HIV-1, HSV (Herpes
Simplex Virus) and HBV [15–17]. Rho A, Rho C, and Rac1
have been reported signiﬁcantly elevated in a variety of
tumors, especially in the more metastatic forms [18, 19].
During the tumor progression, the loss of the cell char-
acteristics results in morphological changes, such as cell-cell
adhesion, gene expression, and motility rate. For example,
the adhesion velocity has been shown to be aﬀected by HBV
replication [20]. Our laboratory has recently reported that2 Journal of Biomedicine and Biotechnology
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Figure 1: Transfection of HepG2 cells using Amaxa Nucleofector and monitored by transient transfection of pEGFP vector: (a) phase
contrastimageofcells48hoursaftertransfection:(b)thecorrespondingimageofthegreenﬂuorescentbypEGFPinthesameﬁeld(Olympus
IX71 ﬂuorescent microcopy).
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Figure2:Westernblotanalysis,(a)expressionofRac1wt,Rac1
G12V,
and Rac1
T17N by western blotting. The internal control was β-actin,
(b) RT-PCR on the expression of HBsAg and HBcAg of Wild-
type HBV replicative genome and P-A mutant HBV genome. The
negative controls was HepG2 cells transfected by empty vector
pcDNA3.1. β-actin was the internal control.
HBV-replicating HepG2 cells display similar morphology
with those expressing the constitutively activated Rac1,
mediated by HBx [17]. We have also shown that HBV
can activate Rac1 GTPases and induce membrane ruﬄing.
HBX can directly interact with a Rac1 nucleotide exchange
factor βPIX, by an SH3 binding motif and aﬀect the cell
morphology [17]. Our data are in line with earlier reports
on the potential invasion ability of HBX through indirect
activation of matrix metalloproteinase (MMPs) [21, 22]. We
nowreportthattheRac1GTPasewasinvolvedsynergistically
with HBX in the migration of HBV-replicating cells. Our
ﬁndings should provide new insights on the mechanism of
development of HCC.
2.MaterialsandMethods
2.1. Plasmids Construction and DNA Manipulation. The
replicative HBV genome comprising a 3.5kb linear fragment
was constructed as described [23] in mammalian expression
vectorpcDNA3.1(Invitrogen,USA),usingatwostepcloning
strategy.
Wild-type replicative HBV genome was used as
template to generate proline to alanine mutation by site-
directed mutagenesis as described in [17]. Four prolines
in HBX on the replicative genome were mutated into
alanine: ESRGR29PLPG33PLGALPPAS42P43PIVPTDH to
ESRGR29ALPG33ALGALPPAS42A43AIVPTDH. Mutations
were conﬁrmed by DNA sequencing.
The plasmids of Rac1 wide type, constitutively activated
Rac1G12V, and dominant negative Rac1T17N were constructed
into a mammalian vector pXJ40 with a HA tag at N-terminal
as described in [24, 25].
2.2. Cell Culture and Transfection. HepG2 cells were main-
tained and passaged in Gibco Dulbecco’s Minimal Essential
Medium, supplemented with 10% fetal bovine serum, 1%
antimycotic, and controlled 5% CO2. Transfections were
performed using Nucleofection solution V (Amaxa GmBH)
as described in [17].
2.3. RNA Extraction and RT-PCR. RNA of the HepG2
cells transfected with various plasmids was extracted using
RNeasy Mini kit (QIAGEN, USA) as described in [17].
DNase I digestion were applied to the extracted RNA to
removegenomeDNAcontamination.Theconcentrationand
quality of RNA were obtained by the absorbance at OD260
and the absorbance ratio of OD260 and OD280.
RT-PCR was performed to conﬁrm gene expression
from the replicative HBV genome as described in [17].Journal of Biomedicine and Biotechnology 3
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Figure 3: Cell motility assay: microscopic examination of cells (red dots by staining) migrated from the upper side to the lower side of the
collagen-coated membrane (Olympus IX 71 microscope). Representative cells were indicated by arrow heads. (a) HepG2 cells transfected
by Wild-type Rac1; (b) HepG2 cells transfected with Rac1
G12V; (c) HepG2 cells transfected by Rac1
T17N; (d) HepG2 cells transfected with
Wild-type Rac1 and Wild-type HBV genome; (e) HepG2 cells transfected with Rac1 wt and P-A mutant HBV genome; (f) HepG2 cells
transfected with Wild-type HBV genome; (g) HepG2 cells transfected with P-A mutant HBV genome.
T h ep r i m e r su s e df o rR T - P C Rw e r ea sf o l l o w s :
β-actin forward: 5 -CTTAGTTGCGTTACACCC-
TTTC-3 ,
β-actin reverse: 5 -ACCTTCACCGTTCCAGTTTT-
3 ,
HBsAg forward: 5 -TCACCATATTCTTGGGAA-
CAA-3 ,
HBsAg reverse: 5 -GTTTTGTTAGGGTTTAAATG-
3 ,
HBcAg forward: 5 -ATCTCCTAGACACCGCCT-
CA-3 ,
HBcAg reverse: 5 -TTCCAAATTATTACCCACCC-
3 .
2.4.WesternBlotAnalysis. HepG2cellstransfectedwithindi-
vidual constructs were collected 48 hours after transfection.
Total protein was extracted by cell lysis buﬀer. Western blot
analysis was carried out using speciﬁc anti-HA or anti-actin
antibodies as described [17].
2.5. Cell Motility by Transwell Assay. Cell motility was
assessed by Transwell Migration Assay kit (BD Falcon, USA).
The inserts were put into the 24-well plate and both sides
of the membrane of the inserts were coated with collagen
(Bioscience, USA) for more than 2 hours. 36 to 48 hours
after transfection, the HepG2 cells were trypsinized and
cell number was adjusted to 20,000–30,000 cells per 200μl
volumebycellnumbering.Thecellsuspensionwasdeposited
onto the collagen-coated membrane in each insert in the 24-
well plate. The plate was put into 37
◦C, 5% CO2 incubator
and cultured for 8 hours to overnight. This was needed
to allow cell migration to take place, from the upper side
to the lower side of the collagen-coated membrane. The4 Journal of Biomedicine and Biotechnology
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Figure 4: Graphical representation of cell motility: lane 1, motility
of cells expressing wild-type Rac1 alone (indicated as Rac1 wt);
lane 2, cells expressing constitutively activated Rac1
G12V (indicated
as Rac1 V12); lane 3, cells expressing dominant negative Rac1
T17N
(indicated as Rac1 N17); lane 4, cells coexpressing Wild-type Rac1
and Wild-type replicative HBV genome (indicated as Rac1 wt &
HBV wt); lane 5, cells expressing Wild-type Rac1 and P-A mutant
replicative HBV genome (indicated as Rac1 wt & HBV mutant);
lane 6, cells expressing wile type replicative HBV genome (indicated
as HBV wt); lane 7, cells expressing P-A mutant replicative HBV
genome (indicated as HBV mutant).
Table 1: Normalized densities of the bands in Figure 2(a).T h e
densities of Rac1 wt were taken as 1 fold.
Antibody pXJ40 Rac1wt Rac1V12 Rac1N17
Anti-HA 0 1 1.148 0.818
Anti-β-actin 1.076 1 1.034 1.028
medium was then removed and the upside cells of the
inserts were gently mopped with cotton bars. The cells at
the lower side of the membrane were ﬁxed with 100%
methanol for 15 minutes. The cells were stained with
0.04% Giemsa solution (Sigma Aldrich, USA) for 10–15
minutes. The membrane was washed with saline solution
and dried up. Four ﬁelds were randomly selected in each
insert for counting and microscopic images were taken.
Three independent experiments were carried out for cells
transfected with each type of construct.
3. Results
HepG2 cells were transfected using Nucleofector to achieve
high eﬃciency of transfection, as indicated by the high
percentage of cells expressing EGFP (Figure 1).
The expression of HBsAg from the replicative genome in
transfected HepG2 cells was assessed by RT-PCR, whereas
the expression of Wild-type Rac1, Rac1G12V,R a c 1 T17N was
determined by Western blot analysis using anti-HA anti-
body.How ever β-actin was used as an internal control.
Results were shown in Figure 2 and Table 1 showed the
normalized densities of the bands shown in Figure 2(a).
The density levels of Rac1 wt were used as standards, other
bands were normalized based on it. It indicated that all
three constructs of Rac1 GTPase were successfully expressed
in HepG2 cells at comparable level. In addition, both
HBsAg and HBV core antigen (HBcAg) could be detected
in HepG2 cells transfected by replicative HBV genome (lane
2, Figure 2(b)) and P-A mutant HBV (lane 3, Figure 2(b)),
with the empty vector pcDNA3.1 used as control (lane 1,
Figure 2(b)).
The motility of HepG2 cells expressing Rac1 alone, and
those expressing both Rac1 and replicative HBV genome was
then analysed by transwell assay, as indicated by the number
of cells migrated to the lower side of the collagen-coated
membrane (see Section 2). Seven sets of constructs were
used in this analysis: Wild-type Rac1 alone; constitutively
activatedRac1G12V alone;dominant negative Rac1T17N alone;
Wild-type Rac1 and Wild-type HBV genome; Wild-type
Rac1andP-AmutantHBVgenome;Wild-typeHBVgenome
alone; and P-A mutant HBV genome alone. Results shown
in Figure 3 indicated that HepG2 cells displayed diﬀerential
motility depending on the transfected constructs, with the
highest number of cells (indicated by arrow heads) in cells
transfected either with Rac1G12V alone (Figure 3(b))o rw i t h
Wild-type Rac1/Wild-type HBV genome (Figure 3(d)). A
graphical representation of the motility assay was summa-
rized in Figure 4 after cell counting and analysis. HepG2
cells transfected with the constitutively activated Rac1G12V
showed a 2.5-fold increase in cell motility (lane 2, Figure 4)
as compared with those expressing Wild-type Rac1 alone
(lane 1, Figure 4) or those expressing the dominant negative
Rac1T17N (lane 3, Figure 4). Interestingly, cells co-transfected
with Wild-type Rac1 and replicative HBV genome showed
similar motility as those transfected with constitutively
activated Rac1G12V. This suggested that the cell motility was
enhanced by HBV replication, likely via activation of Wild-
type Rac1 to its GTP-bound state as recently reported [17].
To validate our ﬁndings, the P-A mutant HBV genome
(with four proline residues mutated to alanine residues in
the proline rich domain) was co-transfected with the Wild-
type Rac1. Results shown in Figure 4 (lane 5) indicated that
the P-A mutant HBV genome abrogated the cell motility
signiﬁcantly, to a level comparable with expressing cells.
Meanwhile, the expression of replicative HBV genome itself
enhanced the cell migration also (lane 6), which may imply
the endogenous Rac1 activation by the HBV replication.
Not surprisingly, the P-A mutant HBV genome abrogated
the cell motility (Lane 7). How ever the cell migration level
caused by endogenous Rac1 was less than that caused by the
overexpressed Rac1 V12, which suggested that endogenous
Wild-type Rac1 was not suﬃcient for the activation caused
by HBV replication. And such activation was conﬁrmed by
the augmentation of cell movements induced by overex-
pression of Rac1 wt. In other words, the endogenous Rac1
was enough to be activated by HBV replication and passed
away cellular signal inducing high cell motility, but the over-
expressed Rac1 can even increase such activation in a certain
degree.
Taken together, our results suggested that the cell migra-
tioncanbecausedbyHBVreplicationthroughtheactivation
of Rac1 GTPase.Journal of Biomedicine and Biotechnology 5
4. Discussion
Rho GTPases comprise a family of proteins which are
highly conserved from lower eukaryotes to plants and
animals [26]. Rho GTPases were implicated in various
cellular processes including cytoskeletal reorganization, cell
cycle and division, motility, angiogenesis, and phagocytosis
[27] .F o rc y t o s k e l e t a lr e o r g a n i z a t i o n ,p r o c e s s e ss u c ha sc e l l
adhesion, cell migration, cell polarity, spindle formation and
locomotion were covered.
It has been reported that the HBX activates ERKs
and PI-3k/akt pathways25, and further activates matrix
metalloproteinase-919 with a potential function of invasion
and metastasis. We have recently demonstrated the same
activation of ERK1/2 and AKT by HBX using SH3 binding
domain located in HBX. Our recent investigation has also
indicated that Rac1 GTPase can be activated by HBV
replication, which in turn sustains HBV replication [17].
Interestingly, the activation of Rac1 and HBV replication has
been found to be signiﬁcantly decreased in cells transfected
with P-A mutant HBV genome. Our ﬁndings can be further
validated by careful design of HBx knockdown in the context
of the whole HBV genome, without aﬀecting the proper
viral replication. Furthermore, the involvement of Rac1 can
be supported by titration experiments in which the same
amount of HBV genome is introduced into the cells with
various amount of Rac1 (activated V12 or inactivated N17).
Findings in this report have provided an extension on
the consequences of the Rac1 activation by HBV replication,
in terms of cell motility. To our knowledge, this is the ﬁrst
report to show the potential relationship between proline
rich domain in HBX (in the context of HBV replication)
and cell motility, and should shed new lights on the
understanding of the mechanism of HCC development.
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